Compugen (CGEN) Reports Positive Data on CGEN-25007
More News related to CGEN
- Morning Movers 11/09: EWBC, CVM, REV, CGEN, RSH Higher; CHDX, SRZ, GTN, RPRX, VSR Lower
- Compugen (CGEN) Announces Discovery of Biomarker CGEN-40001 for Type 2 Diabetes
- Compugen Announces Discovery of Genetic Biomarker for Predisposition to Type 2 Diabetes
- Compugen Announces Preeclampsia Biomarker Collaboration
- Compugen Reports Third Quarter 2009 Financial Results
Compugen Ltd. (NASDAQ: CGEN) announced that CGEN-25007, a novel peptide antagonist of gp96 with potent anti-inflammatory activity, has shown positive therapeutic effects in an animal model of inflammatory bowel disease (IBD), a commonly used term covering ulcerative colitis and Crohn's disease.
CGEN-25007 was initially discovered using Compugen's Disease-Associated Conformation (DAC) blockers discovery platform. This platform was designed for the systematic discovery of novel peptides that block proteins of interest from achieving certain disease-associated conformations, a capability that represents immense therapeutic promise in numerous fields. The platform is based on the integration of methods and ideas varying from information theory, through machine learning and statistics, to mathematical analysis for detecting intra-molecular interactions within the protein of interest.
Compugen is a drug and diagnostic product candidate discovery company. [SM]
Related Categories
Corporate NewsStocks Mentioned
-0.03Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
